CliffBio
small molecule

IVERMECTIN

IVERMECTIN

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameIVERMECTIN
Active ingredientIVERMECTIN
Strength0.5%
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusOTC

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.